功能障碍和晚期毒性:比较丸癌的现代化疗方案在现实世界中设置
Sarah L Kerns1, Paul C Dinh2, Patrick O Monahan3
11Department of Radiation Oncology, The Medical College of Wisconsin, Milwaukee, WI.
Journal of the National Comprehensive Cancer Network : JNCCN
|February 16, 2026
概括
经过长期丸癌幸存者治疗以埃托波/西斯普拉丁 (EPx4) 或白素/埃托波/西斯普拉丁 (BEPx3) 显示类似的累计病率负担. 然而,与BEPx3.3相比,EPx4与功能障碍,耳毒性和神经病变的增加有关.
科学领域:
- 在瘤学瘤学.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
背景情况:
- 丸癌幸存者 (TCS) 面临着长期的健康挑战.
- 当代NCCN认可的化学疗法方案,如埃托波/西斯普拉丁 (EPx4) 和白素/埃托波/西斯普拉丁 (BEPx3/BEPx4),被广泛使用.
- 在长期TCS中量化累积病情负担 (CBM) 对于理解治疗后果至关重要.
研究的目的:
- 在长期丸癌幸存者中量化CBM得分,包括功能.
- 为了比较不同化疗方案 (EPx4,BEPx3,BEPx4,VIPx4) 之间的CBM分数和不良健康结果 (AHO).
- 调查西斯普拉丁剂量,估计的淋巴细胞过率 (eGFR) 和随后的AHOs之间的关联.
主要方法:
- 一组798名丸癌幸存者 (TCS) 接受了临床检查并填写了问卷.
- 计算了累积病情负担 (CBM) 评分和不良健康结果 (AHO) 的严重程度等级.
- 用调整的顺序逻辑回归和相关性分析来评估治疗效应和关联.
主要成果:
- 与BEPx3相比,接受EPx4的TCS患功能障碍,耳毒性和神经病变的几率更高.
- 在41%的TCS中观察到降低的eGFR (<90毫升/分钟/1.73米2),并与西斯普拉丁剂量相关.
- 降低的EGFR与高血压,高脂血症和心血管疾病 (CVD) 的几率增加相关.
结论:
- 在EPx4和BEPx3之后的长期CBM得分是可比的,但EPx4与更高的西斯相关毒性有关.
- 西斯普拉丁剂量依赖的EGFR降低预测高血压,高脂血和心血管疾病的显著增加.
- 现实世界的数据强调了监测功能和丸癌症幸存者的相关并发症的重要性.
相关概念视频
Renal Drug Clearance: Comparison Between Renal Excretion Methods
666
Renal clearance is a critical parameter encompassing kidney filtration, secretion, and reabsorption processes. It is calculated using a specific equation to determine the rate at which the kidneys clear a drug.
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...
666
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
264
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
264
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
239
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
239
Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance
241
In healthy individuals, serum creatinine levels remain stable due to a balance between its constant production—primarily from muscle metabolism—and renal excretion. Creatinine is freely filtered by the glomeruli, making it a valuable marker for estimating renal function. When the glomerular filtration rate (GFR) decreases, the kidneys can only eliminate less creatinine, causing serum levels to rise.Serum creatinine concentration is widely used to estimate creatinine clearance...
241
Toxicity Testing in Animals
23
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
23
Renal Drug Clearance: Overview
848
Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
848


